Abstract
Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative “endothelial progenitor cells” (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed “EPCs”, including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of “EPCs” in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.
Keywords: Cell therapy, cardiovascular disease, cell dysfunction, endothelial progenitor cells, diabetes, hypertension, ROS, angiogenesis, macrovasculature, kallikrein-kinin-system
Current Vascular Pharmacology
Title: “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Volume: 10 Issue: 1
Author(s): Nicolle Krankel, Thomas F. Luscher and Ulf Landmesser
Affiliation:
Keywords: Cell therapy, cardiovascular disease, cell dysfunction, endothelial progenitor cells, diabetes, hypertension, ROS, angiogenesis, macrovasculature, kallikrein-kinin-system
Abstract: Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and mortality throughout middle- and high-income countries. More efficient preventive and regenerative therapeutic strategies are therefore urgently needed. The repeated finding that putative “endothelial progenitor cells” (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present review, we discuss the growing knowledge about various distinct cell populations which have been collectively termed “EPCs”, including myeloid cells and progenitor cells of different origin. We also present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In addition, we will discuss recent insights into mechanisms leading to dysfunction of “EPCs” in cardiovascular disease. Those findings may help to optimize autologous cell-based treatment approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.
Export Options
About this article
Cite this article as:
Krankel Nicolle, F. Luscher Thomas and Landmesser Ulf, “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease, Current Vascular Pharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157016112798829832
DOI https://dx.doi.org/10.2174/157016112798829832 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Beta-Blocker in Heart Failure in Adults with Congenital Heart Disease
Reviews on Recent Clinical Trials Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Nitric Oxide in Cardiac Transplantation
Vascular Disease Prevention (Discontinued) Neuregulin1 as Novel Therapy for Heart Failure
Current Pharmaceutical Design Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Cardiovascular & Hematological Disorders-Drug Targets Limitations of Current Antiretroviral Agents and Opportunities for Development
Current Pharmaceutical Design Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry Cardiovascular Diseases and Natural Products
Current Protein & Peptide Science Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Current Opinion and Future Trends)
Current Pharmaceutical Design Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews